

42397

Merck & Co., Inc.  
U.S. Human Health  
P.O. Box 4  
West Point, PA 19486-0004  
Tel: 800-672-6372  
Fax: 800-637-2568

April 8, 2003



Dear

Our Market Manager, George J. Dececco, R.Ph., has referred your request for information regarding COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine]. Your inquiry concerned a Material Safety Data Sheet for COMVAX.

This material is not listed as a carcinogen in the National Toxicology Program (NTP) Annual Report on Carcinogens, latest edition; the International Agency for Research on Cancer (IARC) Monographs, latest edition; or the Occupational Safety and Health Administration's 29 CFR 1910 subpart Z. In addition, it does not have an assigned Threshold Limit Value (TLV) in American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Values for Chemical Substances and Physical Agents in the Work Environment, latest edition, and is not regulated by the Occupational Safety and Health Administration (OSHA). Furthermore, we are unaware of any published studies or literature that establishes that this material is hazardous under the Hazard Communication Standard as defined in 29 CFR 1910.1200 Sections (c) & (d). Hence, a Material Safety Data Sheet is neither required nor available.

The above information is supplied to you as a professional service in response to your specific request. Merck does not recommend the use of its products in any manner other than as described in the prescribing information. Enclosed for your convenience is prescribing information for COMVAX.

Sincerely,

A handwritten signature in cursive script that reads "Charles A. Baechler, Ph.D.".

Charles A. Baechler, Ph.D.  
Senior Manager  
Medical Services

Enclosure: Circular